BACKGROUND: Radiotherapy (RT) is the standard treatment for uveal melanoma. However it can cause damage to the retina and optic nerve. This study examined the in vitro and in vivo effects of the anti-VEGF monoclonal antibody bevacizumab associated with radiotherapy (RT) on tumor growth and tumor proliferation and vasculature on OCM-1 human uveal melanoma cell line. METHODS: The anti-proliferative effects of bevacizumab, RT and their combination were tested both in vitro (OCM-1 cells co-cultured with HUVEC cells in Transwell plates) and in vivo (OCM-1 tumor xenografts in nude mice). In addition, treatment effects in vitro on VEGF secretion, as well as treatment effects in vivo on tumor proliferation (Ki67 labelling), tumor vasculature (VEGFR2 labelling) and VEGF tumoral concentration were analyzed. RESULTS: Bevacizumab given alone had a significant impact on tumor growth in vivo (and moderate effects in vitro). The bevacizumab-RT combination had additive effects in vitro (tumor cell proliferation) and in vivo (tumor growth), which translated into a significant decrease in Ki67 expression, VEGFR2 labelling and VEGF tumoral content. CONCLUSIONS: The bevacizumab-RT combination could be a promising clinical option to explore for the management of human uveal melanoma, since it may allow RT dose reduction without loss of antitumor efficacy.
BACKGROUND: Radiotherapy (RT) is the standard treatment for uveal melanoma. However it can cause damage to the retina and optic nerve. This study examined the in vitro and in vivo effects of the anti-VEGF monoclonal antibody bevacizumab associated with radiotherapy (RT) on tumor growth and tumor proliferation and vasculature on OCM-1humanuveal melanoma cell line. METHODS: The anti-proliferative effects of bevacizumab, RT and their combination were tested both in vitro (OCM-1 cells co-cultured with HUVEC cells in Transwell plates) and in vivo (OCM-1tumor xenografts in nude mice). In addition, treatment effects in vitro on VEGF secretion, as well as treatment effects in vivo on tumor proliferation (Ki67 labelling), tumor vasculature (VEGFR2 labelling) and VEGF tumoral concentration were analyzed. RESULTS:Bevacizumab given alone had a significant impact on tumor growth in vivo (and moderate effects in vitro). The bevacizumab-RT combination had additive effects in vitro (tumor cell proliferation) and in vivo (tumor growth), which translated into a significant decrease in Ki67 expression, VEGFR2 labelling and VEGF tumoral content. CONCLUSIONS: The bevacizumab-RT combination could be a promising clinical option to explore for the management of humanuveal melanoma, since it may allow RT dose reduction without loss of antitumor efficacy.
Authors: K M Egan; E S Gragoudas; J M Seddon; R J Glynn; J E Munzenreider; M Goitein; L Verhey; M Urie; A Koehler Journal: Ophthalmology Date: 1989-09 Impact factor: 12.079
Authors: L Desjardins; C Levy; F d'Hermies; E Frau; P Schlienger; J L Habrand; H Mammar; L Schwartz; A Mazal; S Delacroix; C Nauraye; R Ferrand; B Asselain Journal: Cancer Radiother Date: 1997 Impact factor: 1.018
Authors: Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: Guy S O Missotten; Irene C Notting; Reinier O Schlingemann; Henry J Zijlmans; Chun Lau; Paul H C Eilers; Jan E E Keunen; Martine J Jager Journal: Arch Ophthalmol Date: 2006-10
Authors: K S Adams; D H Abramson; R M Ellsworth; B G Haik; M Bedford; S Packer; J Seddon; D Albert; L Polivogianis Journal: Br J Ophthalmol Date: 1988-07 Impact factor: 4.638
Authors: Jasmina Ziva Cerne; Sean Michael Hartig; Mark Patrick Hamilton; Sue Anne Chew; Nicholas Mitsiades; Vassiliki Poulaki; Sean Eric McGuire Journal: Invest Ophthalmol Vis Sci Date: 2014-04-07 Impact factor: 4.799
Authors: Lia Walcher; Clara Budde; Arina Böhm; Peter S Reinach; Priyavathi Dhandapani; Nina Ljubojevic; Markus W Schweiger; Henriette von der Waydbrink; Ilka Reimers; Josef Köhrle; Stefan Mergler Journal: Front Pharmacol Date: 2018-11-13 Impact factor: 5.810